Microvascular Therapeutics Has Received Funds from the National Heart, Lung and Blood Institute (NHLBI)
Tucson, AZ, July 19, 2021 --(PR.com)-- Microvascular Therapeutics (MVT) has received funds from the from the National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health for its program to treat cardiovascular disease, which kills more Americans than any other disease. As a leader in fluorocarbon technology, MVT is currently developing Phase Shift Microbubbles (PSMB) for several therapeutic applications.
Evan Unger, MD, founder and Interim CEO of MVT said, “This extends our ongoing work in therapeutic PSMB in important ways for patients suffering one of the most difficult to treat diseases. We are optimistic that this will lead to better options for patients.” Dr. Unger has been pioneering the use of fluorocarbons and ultrasound in diagnostics and therapeutics for more than 30 years and is the inventor of Definity®, the leading ultrasound contrast agent.
Dr. John Pacella, MD, interventional cardiologist at the University of Pittsburgh and Dr. Xiaoning Jiang, Ph.D., Dean F. Duncan Distinguished Professor of Mechanical and Aerospace Engineering at the North Carolina State University, Adjunct Professor of Biomedical Engineering at the University of North Carolina at Chapel Hill and North Carolina State University, and Adjunct Professor of Neurology at Duke University, are co-Investigators on this novel R33 award as part of the recently launched NHLBI Catalyze program which aims at “facilitating the transition of basic science discoveries into viable diagnostic and therapeutic candidates cleared for human testing” (Source: NHLBI Catalyze Program | NHLBI, NIH).
The team of MVT hope to translate the discoveries to the clinic in collaboration with SonoVascular. “We are very excited to work with Dr. Unger and the team at MVT on the further development of this exciting technology. Dr. Unger has a proven track record of bringing life-saving technologies to the clinic and fluorocarbon phase shift microbubbles have the potential to make a significant impact in patient care,” said Daniel Estay, CEO of SonoVascular. “SonoVascular, in collaboration with Dr. Xiaoning Jiang’s lab at North Carolina State University, has developed an ultrasound catheter technology which is able to treat blood clots and we will be using the PSMB from MVT. We anticipate to jointly develop the technology for treatment of deep vein thrombosis, arterial occlusions, and pulmonary emboli. These are life-threatening diseases that afflict more than one million Americans each year. This new technology combining therapeutic ultrasound with MVT’s PSMB technology has potential to more rapidly and safely treat vascular disease.”
This new grant from the NHLBI will “allow us to improve on the formulation of our products and test them in combination with the technology of SonoVascular to treat blood clots. This work funded by the NHLBI represents one step closer towards clinical testing,” says the Principal Investigator of the award, Emmanuelle Meuillet, PhD, Chief Scientific Officer of MVT.
About Microvascular Therapeutics (MVT)
Microvascular Therapeutics is a biotechnology company based in Tucson, Arizona and is a leader in microbubble technology. MVT's mission is to develop the next generation of contrast agents for diagnostic ultrasound and advance the field of ultrasound for diagnosis and treatment of disease. The chemists at MVT have developed a new, patented microbubble formulation that can serve as a platform for development of agents for molecular imaging and image-guided therapy. (www.mvtpharma.com)
About SonoVascular
SonoVascular is a medical device company based in Chapel Hill, North Carolina. The company has developed a novel catheter-based approach utilizing therapeutic ultrasound to treat arterial and venous disease, including retracted blood clots which form over extended periods of time, and are especially dense and hard to treat. (www.sonovascular.com)
For further information contact Emmanuelle Meuillet at e.meuillet@mvtpharma.com
Disclaimer: Research reported in this press release is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under the award number 1R33HL156350-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Disclaimer: Certain statements in this release may constitute “forward-looking statements.” Press Release Distribution Terms of Use or results may differ substantially as a result of risks and uncertainties facing us. The forward-looking statements are based on current expectations as of the date of these statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information, or otherwise.
Conflict of Interests: Dr. Xiaoning Jiang at North Carolina State University is a co-founder of SonoVascular, Inc.
Evan Unger, MD, founder and Interim CEO of MVT said, “This extends our ongoing work in therapeutic PSMB in important ways for patients suffering one of the most difficult to treat diseases. We are optimistic that this will lead to better options for patients.” Dr. Unger has been pioneering the use of fluorocarbons and ultrasound in diagnostics and therapeutics for more than 30 years and is the inventor of Definity®, the leading ultrasound contrast agent.
Dr. John Pacella, MD, interventional cardiologist at the University of Pittsburgh and Dr. Xiaoning Jiang, Ph.D., Dean F. Duncan Distinguished Professor of Mechanical and Aerospace Engineering at the North Carolina State University, Adjunct Professor of Biomedical Engineering at the University of North Carolina at Chapel Hill and North Carolina State University, and Adjunct Professor of Neurology at Duke University, are co-Investigators on this novel R33 award as part of the recently launched NHLBI Catalyze program which aims at “facilitating the transition of basic science discoveries into viable diagnostic and therapeutic candidates cleared for human testing” (Source: NHLBI Catalyze Program | NHLBI, NIH).
The team of MVT hope to translate the discoveries to the clinic in collaboration with SonoVascular. “We are very excited to work with Dr. Unger and the team at MVT on the further development of this exciting technology. Dr. Unger has a proven track record of bringing life-saving technologies to the clinic and fluorocarbon phase shift microbubbles have the potential to make a significant impact in patient care,” said Daniel Estay, CEO of SonoVascular. “SonoVascular, in collaboration with Dr. Xiaoning Jiang’s lab at North Carolina State University, has developed an ultrasound catheter technology which is able to treat blood clots and we will be using the PSMB from MVT. We anticipate to jointly develop the technology for treatment of deep vein thrombosis, arterial occlusions, and pulmonary emboli. These are life-threatening diseases that afflict more than one million Americans each year. This new technology combining therapeutic ultrasound with MVT’s PSMB technology has potential to more rapidly and safely treat vascular disease.”
This new grant from the NHLBI will “allow us to improve on the formulation of our products and test them in combination with the technology of SonoVascular to treat blood clots. This work funded by the NHLBI represents one step closer towards clinical testing,” says the Principal Investigator of the award, Emmanuelle Meuillet, PhD, Chief Scientific Officer of MVT.
About Microvascular Therapeutics (MVT)
Microvascular Therapeutics is a biotechnology company based in Tucson, Arizona and is a leader in microbubble technology. MVT's mission is to develop the next generation of contrast agents for diagnostic ultrasound and advance the field of ultrasound for diagnosis and treatment of disease. The chemists at MVT have developed a new, patented microbubble formulation that can serve as a platform for development of agents for molecular imaging and image-guided therapy. (www.mvtpharma.com)
About SonoVascular
SonoVascular is a medical device company based in Chapel Hill, North Carolina. The company has developed a novel catheter-based approach utilizing therapeutic ultrasound to treat arterial and venous disease, including retracted blood clots which form over extended periods of time, and are especially dense and hard to treat. (www.sonovascular.com)
For further information contact Emmanuelle Meuillet at e.meuillet@mvtpharma.com
Disclaimer: Research reported in this press release is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under the award number 1R33HL156350-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Disclaimer: Certain statements in this release may constitute “forward-looking statements.” Press Release Distribution Terms of Use or results may differ substantially as a result of risks and uncertainties facing us. The forward-looking statements are based on current expectations as of the date of these statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information, or otherwise.
Conflict of Interests: Dr. Xiaoning Jiang at North Carolina State University is a co-founder of SonoVascular, Inc.
Contact
Microvascular Therapeutics
Emmanuelle Meuillet
520-730-3264
mvtpharma.com
Emmanuelle Meuillet
520-730-3264
mvtpharma.com
Contact
Categories